Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

THE METABOLIC DISPOSITION OF APREPITANT, A SUBSTANCE P RECEPTOR ANTAGONIST, IN RATS AND DOGS

Su-Er W. Huskey, Brian J. Dean, George A. Doss, Zhen Wang, Cornelis E.C.A. Hop, Reza Anari, Paul E. Finke, Albert J. Robichaud, Minghua Zhang, Bonnie Wang, John R. Strauss, Paul K. Cunningham, William P. Feeney, Ronald B. Franklin, Thomas A. Baillie and Shuet-Hing L. Chiu
Drug Metabolism and Disposition February 2004, 32 (2) 246-258; DOI: https://doi.org/10.1124/dmd.32.2.246
Su-Er W. Huskey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian J. Dean
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George A. Doss
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhen Wang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cornelis E.C.A. Hop
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Reza Anari
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul E. Finke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Albert J. Robichaud
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Minghua Zhang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bonnie Wang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John R. Strauss
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul K. Cunningham
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William P. Feeney
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald B. Franklin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas A. Baillie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shuet-Hing L. Chiu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The absorption, metabolism, and excretion of [14C]aprepitant, a potent and selective human substance P receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting, was evaluated in rats and dogs. Aprepitant was metabolized extensively and no parent drug was detected in the urine of either species. The elimination of drug-related radioactivity, after i.v. or p.o. administration of [14C]aprepitant, was mainly via biliary excretion in rats and by way of both biliary and urinary excretion in dogs. Aprepitant was the major component in the plasma at the early time points (up to 8 h), and plasma metabolite profiles of aprepitant were qualitatively similar in rats and dogs. Several oxidative metabolites of aprepitant, derived from N-dealkylation, oxidation, and opening of the morpholine ring, were detected in the plasma. Glucuronidation represented an important pathway in the metabolism and excretion of aprepitant in rats and dogs. An acid-labile glucuronide of [14C]aprepitant accounted for ∼18% of the oral dose in rat bile. The instability of this glucuronide, coupled with its presence in bile but absence in feces, suggested the potential for enterohepatic circulation of aprepitant via this conjugate. In dogs, the glucuronide of [14C]aprepitant, together with four glucuronides derived from phase I metabolites, were present as major metabolites in the bile, accounting collectively for ∼14% of the radioactive dose over a 4- to 24-h period after i.v. dosing. Two very polar carboxylic acids, namely, 4-fluoro-α-hydroxybenzeneacetic acid and 4-fluoro-α-oxobenzeneacetic acid, were the predominant drug-related entities in rat and dog urine.

Footnotes

  • ↵1 Abbreviations used are: NK1, neurokinin 1; aprepitant (MK-0869), 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one; SD, Sprague-Dawley; M-1, (2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholine; M-2, (2R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-5,6-dihydro-2H-1,4-oxazine; M-3, (5S,6R)-6-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-5-(4-fluorophenyl)-3-morpholinone; M-4, (6R)-6-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-5-(4-fluorophenyl)-5-hydroxy-3-morpholinone; M-5, [(1R)-1-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-2-(4-fluorophenyl)-2-oxoethoxy] acetic acid; M-6, [(1R)-1-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-2-(4-fluorophenyl)-2-hydroxyethoxy]acetic acid; M-8, (2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholineacetic acid; M-9, α-[(R)-[(1R)-[3,5-bis(trifluoromethyl) phenyl]ethoxy](2-hydroxyethoxy) methyl]-4-fluorobenzenemethanol; M-10, 4-fluoro-α-hydroxybenzeneacetic acid; M-11, 4-fluoro-α-oxobenzeneacetic acid; M-12, 4-fluorophenylglycine; M-13, (αS)-4-fluoro-α-[[(2,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)methyl] amino]benzeneacetic-carboxy acid; M-14, 5-[[(1S)-1-(4-fluorophenyl)-2-hydroxyethyl-2-amino]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one; HPLC, high-performance liquid chromatography; LC-MS/MS, liquid chromatography-tandem mass spectrometry; TFA, trifluoroacetic acid; MEK, methyl ethyl ketone; NOE, nuclear Overhauser effect.

    • Received June 13, 2003.
    • Accepted October 2, 2003.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 32 (2)
Drug Metabolism and Disposition
Vol. 32, Issue 2
1 Feb 2004
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
THE METABOLIC DISPOSITION OF APREPITANT, A SUBSTANCE P RECEPTOR ANTAGONIST, IN RATS AND DOGS
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

THE METABOLIC DISPOSITION OF APREPITANT, A SUBSTANCE P RECEPTOR ANTAGONIST, IN RATS AND DOGS

Su-Er W. Huskey, Brian J. Dean, George A. Doss, Zhen Wang, Cornelis E.C.A. Hop, Reza Anari, Paul E. Finke, Albert J. Robichaud, Minghua Zhang, Bonnie Wang, John R. Strauss, Paul K. Cunningham, William P. Feeney, Ronald B. Franklin, Thomas A. Baillie and Shuet-Hing L. Chiu
Drug Metabolism and Disposition February 1, 2004, 32 (2) 246-258; DOI: https://doi.org/10.1124/dmd.32.2.246

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

THE METABOLIC DISPOSITION OF APREPITANT, A SUBSTANCE P RECEPTOR ANTAGONIST, IN RATS AND DOGS

Su-Er W. Huskey, Brian J. Dean, George A. Doss, Zhen Wang, Cornelis E.C.A. Hop, Reza Anari, Paul E. Finke, Albert J. Robichaud, Minghua Zhang, Bonnie Wang, John R. Strauss, Paul K. Cunningham, William P. Feeney, Ronald B. Franklin, Thomas A. Baillie and Shuet-Hing L. Chiu
Drug Metabolism and Disposition February 1, 2004, 32 (2) 246-258; DOI: https://doi.org/10.1124/dmd.32.2.246
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • BSEP Function in Suspension Hepatocytes
  • Candesartan glucuronide serves as a CYP2C8 inhibitor
  • Role of AADAC on eslicarbazepine acetate hydrolysis
Show more Articles

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics